Advertisement

Organisation › Details
PsiOxus Therapeutics Ltd.
PsiOxus Therapeutics is an Oxford, UK-based development stage biotechnology company with a particular focus in immune therapeutics in oncology. PsiOxus has developed a patented platform for tumour-targeted delivery based on its oncolytic vaccine, enadenotucirev. Enadenotucirev’s unique design allows it to be delivered systemically via intravenous administration. The anti-cancer scope of enadenotucirev can be expanded through “arming” – a process that involves addition of new genes into enadenotucirev. The "Armed EnAd" platform makes possible creation of a broad range of unique oncolytic immune therapeutics, including oncolytic vaccines that express one or more antibodies (AbEnAd), cytokines or other immunomodulatory proteins, or nucleotide based payloads such as RNAi. The Armed EnAd platform is in preclinical stage, while phase I/II clinical trials are ongoing with the parent unarmed EnAd in different tumour types. *
![]() |
Start | 2010-12-15 merged |
![]() |
End | 2023-01-05 renamed |
Group | Akamis Bio (Group) | |
Today | Akamis Bio Ltd. | |
Predecessor | Myotec Therapeutics Ltd. | |
Successor | Akamis Bio Ltd. | |
![]() |
Industry | oncolytic virus (cancer-cilling virus, virotherapy for cancer, virus-based cancer therapy) |
![]() |
Person | Davis, Howard E. (PsiOxus 202208– CEO based in Boston area before Atlas Venture + Third Harmonic Bio + Flagship) |
Person 2 | Paoletti, Paolo (GammaDelta Therapeutics 201705– CEO before Kesios Therapeutics CEO + GSK) | |
![]() |
Region | Abingdon, Oxfordshire |
Country | United Kingdom (GB) | |
Street | 154B Brook Drive Milton Park | |
City | OX14 4SD Abingdon, Oxfordshire | |
Tel | +44-1235-835328 | |
Address record changed: 2020-12-02 | ||
Basic data | Employees | n. a. |
* Document for »About Section«: | ||
Record changed: 2023-07-10 |
Advertisement

More documents for Akamis Bio (Group)
- [1] Akamis Bio Ltd.. (1/5/23). "Press Release: Akamis Bio Announces $30 Million Financing, Provides Clinical Program Update and Relaunches with Name Change from PsiOxus Therapeutics". Cambridge, MA & Oxford....
- [2] PsiOxus Therapeutics Ltd.. (8/11/22). "Press Release: PsiOxus Therapeutics Appoints Howard Davis, Ph.D. as Chief Executive Officer". Oxford....
- [3] Crescendo Biologics Ltd.. (4/4/19). "Press Release: Theodora Harold to Be Appointed New CEO at Crescendo Biologics". Cambridge....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to [email protected] and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement

» top